The Big Question in EGFR-Mutant Lung Cancer: A Targeted Pill Alone, or a Combined Approach?

Is a Targeted Drug Alone Enough, or Is Combination Treatment Needed?

Cancer treatment has followed a basic principle for the past 50 years: strength in unity. The major success achieved in Hodgkin lymphoma by combining chemotherapies in the 1970s is now taking on a new dimension in lung cancer, the world’s deadliest cancer.

For a long time, osimertinib, a targeted pill, was the standard standalone treatment for EGFR-mutated non-small-cell lung cancer (NSCLC). However, a comprehensive editorial analysis in the New England Journal of Medicinefirst issue of 2026 emphasizes that this approach is changing. Major trials such as FLAURA2 and MARIPOSA show that adding chemotherapy or other biological agents to targeted drugs extends survival to previously unimaginable levels—4 years and beyond. But this success comes at a cost: increased side effects.

Major First-Line Competition: FLAURA2 and MARIPOSA

In the editorial, Dr. Roy S. Herbst examines two critical trials. Their shared question is: "What happens if, instead of giving the best drug—osimertinib—alone, we add another source of strength?"

• The FLAURA2 Trial: Conventional chemotherapy was added to osimertinib, significantly improving survival compared with the pill alone. However, side effects of grade 3 or higher increased from 34% to 70%.
• The MARIPOSA Trial: Instead of osimertinib, the trial tested lazertinib (another targeted pill) + amivantamab (an intravenous biological drug). This chemotherapy-free combination also provided longer disease control than osimertinib alone (23.7 months versus 16.6 months). However, side effects such as blood clots and skin rashes were more frequent.

What Happens if Resistance Develops? "Smart Missiles" Enter the Stage

Our options used to be limited when first-line osimertinib stopped working. However, a new study published in this issue demonstrated that Sacituzumab tirumotecan (sac-TMT) , a next-generation ADC targeting TROP-2, was superior to standard chemotherapy. In patients who developed resistance after targeted treatment, sac-TMT almost doubled the time before disease progression compared with chemotherapy (8.3 months versus 4.3 months).

The Patient's Perspective: Which Treatment Is Right for Me?

Although scientific data show that combination treatment is more effective, this does not mean it should immediately be used for every patient. Decisions should weigh the following:

• Who Should Receive an Aggressive Approach (Combination)? For patients with brain metastases, a high tumor burden, or high-risk genetic features, accepting side effects to apply full pressure from the outset may be reasonable.
• Who Should Receive a "Lighter" Approach (Monotherapy)? For older patients, those with other illnesses, or those prioritizing quality of life, osimertinib alone remains a strong, valid standard.

The Biological Foundations of Lung Cancer

Figure 1: The Basic Features of Lung Cancer and Treatment Approaches. This figure summarizes cancer's complex nature (the Hallmarks of Cancer) and the strategies developed against it.

• Inner Circle (Tumor Mechanisms): Shows the main biological processes determining lung tumor behavior. These include oncogenic pathway activation (e.g., EGFR, ALK, or KRAS mutation), loss of growth control, resistance to cell death, new blood vessel formation (angiogenesis), and immune evasion.
• Outer Circle (Treatment Approaches): Shows our tools for targeting these mechanisms: targeted therapy (e.g., EGFR inhibition), chemotherapy, bispecific antibodies, metabolic inhibitors, angiogenesis inhibitors, and next-generation antibody–drug conjugates (ADCs).
• Stages: Treatment approaches around the figure indicate that the most effective drugs are now used not only in advanced disease but from its earliest stages. (Adapted from Hanahan and Weinberg.)